How much funding has Biomotion raised?

Biomotion has raised $9.9M in total funding. Key investors include Austria Wirtschaftsservice (AWS); FFG (Austrian Research Promotion Agency).

Who is the CEO of Biomotion?

Gregor Weisgrab is the CEO of Biomotion. The company was founded in 2024.

Where is Biomotion located?

Biomotion is headquartered in Vienna, Austria.

What funding stage is Biomotion at?

Biomotion is currently at the Active stage.

How many employees does Biomotion have?

Biomotion has approximately 1-10 employees.

Biomotion

Name: AM Companies Database
Creator: AMPulse
License: https://creativecommons.org/licenses/by/4.0/

HardwareVienna, AustriaFounded 2024· One of 1702 Hardware companies tracked by AMPulse

Develops an automated 3D bioprinting platform with integrated machine learning co-pilots to standardize human tissue fabrication for pharmaceutical drug screening.

CEO / Founder: Gregor Weisgrab
Team Size: 1-10
Stage: Active
Total Funding: $9.9M
Latest Round: Grant
Key Investors: Austria Wirtschaftsservice (AWS); FFG (Austrian Research Promotion Agency)

Technology & Products

Key Products

ExplorerONE Bioprinting Platform; Machine Learning Bioprinting Co-pilot Software; Custom Biofabrication Workflows

Technological Advantage

Standardizes the traditionally variable bioprinting process, enabling high-throughput, reliable tissue production for drug toxicity and efficacy testing.

Differentiation

Value Proposition

Reduces drug screening variability and experimental failure rates by automating the biofabrication of human tissues using real-time ML monitoring to ensure reproducible results.

How They Differentiate

Focuses on process reliability through automated ML-driven parameter optimization, addressing the industry's primary bottleneck of bioprinting reproducibility.

Market & Competition

Target Customers

Pharmaceutical companies, contract research organizations (CROs), and biomedical research institutions.

Industry Verticals

Medical; Pharmaceutical; Biotechnology

Competitors

CELLINK; regenHU; Aspect Biosystems; Organovo

Growth & Milestones

Growth Metrics

Winner of 'Rise & Pitch' 2024 at Digital Demo Day by Rise Europe; Finalist for the Formnext Awards 2025 in the Start-up category.

Major Milestones

Founded in 2024; Launched ExplorerONE bioprinting platform; Winner of Rise & Pitch 2024; Finalist for Formnext Awards 2025

Notable Customers

UAS Technikum Wien (University of Applied Sciences Technikum Wien); TU Eindhoven (Eindhoven University of Technology)

https://www.biomotion.tech

Why this company matters

Biomotion Technologies FlexCo addresses a core bottleneck in pharmaceutical development: the lack of reproducibility in bioprinted human tissues for drug screening. While existing bioprinting platforms produce variable results due to manual parameter tuning, Biomotion integrates real-time machine learning co-pilots that dynamically adjust printing parameters based on sensor feedback. This automation aims to standardize tissue fabrication, reducing experimental failure rates and enabling high-throughput toxicity and efficacy testing.

The company's flagship product, the ExplorerONE Bioprinting Platform, uses material extrusion (MEX) to print cell-laden hydrogels. Its ML co-pilot software monitors the printing process and corrects deviations in real time, a capability that differentiates it from competitors like CELLINK, regenHU, and Aspect Biosystems. Biomotion also offers custom biofabrication workflows tailored to specific tissue models.

Target customers include pharmaceutical companies, contract research organizations (CROs), and biomedical research institutions. The company has early partnerships with TU Wien and Rise Europe, and its technology is being evaluated by UAS Technikum Wien and Eindhoven University of Technology. Biomotion was a finalist for the Formnext 2025 Start-up Award and won the Rise & Pitch 2024 competition.

Founded in 2024 and based in Vienna, the startup has raised €9.2 million from Austria Wirtschaftsservice and the FFG. Its key open question is whether its ML-driven approach can scale from academic partnerships to commercial adoption by large pharma, where validation timelines are long. The company's focus on process reliability positions it as a niche player in the emerging bioprinting-for-drug-screening segment.